Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

A method of treating a condition selected from the group consisting of cancers, auto-immune diseases, and immune system diseases in a subject in need thereof, comprising administration of a compound of formula (I):

• wherein:
• Het represents a heteroaryl group;
• T represents a hydrogen atom, a linear or branched (C1-C6)alkyl group, an alkyl(C1-C4)—NR1R2 group or an alkyl(C1-C4)—OR6 group;
• R1 and R2 independently of one another represent a hydrogen atom or a linear or branched (C1-C6)alkyl group,
• or R1 and R2 form with the nitrogen atom carrying them a heterocycloalkyl group;
• R3 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl group, a (C3-C10)cycloalkyl-(C1-C6)alkyl group wherein the alkyl group may be linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, wherein one or more carbon atoms of the groups defined hereinbefore, or carbon atoms of their possible substituents, may be deuterated;
• R4 represents an aryl, heteroaryl, cycloalkyl or linear or branched (C1-C6)alkyl group, wherein one or more carbon atoms of the groups defined hereinbefore, or carbon atoms of their possible substituents, may be deuterated;
• R5 represents a hydrogen atom or a halogen atom, a linear or branched (C1-C6)alkyl group, or a linear or branched (C1-C6)alkoxy group;
• R6 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group;
• R7 represents a group selected from R′7, R′7—CO—, R′7—O—CO—, NR′7R″7—CO—, R′7—SO2—, and R′7—NR″7—SO2— wherein R′7 et R″7 independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl, a heterocycloalkyl, an aryl group, or a heteroaryl;
• R8 and R9 represent, independently of one another, an oxo group or a halogen atom;
• p and p′ are, independently of one another, integers equal to 0, 1, 2, 3 or 4;
• q and q′ are, independently of one another, integers equal to 1, 2 or 3;
• wherein when the compound of formula (I) contains a hydroxy group, this latter group may be optionally substituted by one of the following groups:
• —PO(OM)(OM′), —PO(OM)(O−M1+), —PO(O−M1+)(O−M2+), —PO(O−)(O−)M32+, —PO(OM)(O[CH2CH2O]nCH3), or —PO(O−M1+)(O[CH2CH2O]nCH3), wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a cycloalkyl or a heterocycloalkyl, both the cycloalkyl and heterocycloalkyl being composed of from 5 to 6 ring members, M1+ and M2+ independently of one another represent a pharmaceutically acceptable monovalent cation, M32+ represents a pharmaceutically acceptable divalent cation and n is an integer comprised between 1 to 5,
• wherein:
• “aryl” means a phenyl, naphthyl, biphenyl or indenyl group,
• “heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and having from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen,
• “cycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group having from 3 to 10 ring members, which may include fused, bridged or spiro ring systems,
• “heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group, composed of from 3 to 10 ring members, and having from one to 3 hetero atoms selected from oxygen, sulphur, SO, SO2 and nitrogen, wherein the bicyclic group may be fused or spiro type,
• wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy, may be optionally substituted by from 1 to 3 groups selected from the group consisting of:
• linear or branched (C1-C6)alkyl group;
• linear or branched (C2-C6)alkenyl group;
• linear or branched (C2-C6)alkynyl group;
• (C3-C6)spiro;
• linear or branched (C1-C6)alkoxy;
• (C1-C6)alkyl-S—;
• hydroxyl;
• oxo;
• N-oxide;
• nitro;
• cyano;
• —COOR′;
• —OCOR′;
• —NR′R″;
• R′CONR″—;
• NR′R″CO—;
• linear or branched (C1-C6)polyhaloalkyl;
• trifluoromethoxy;
• (C1-C6)alkylsulphonyl;
• halogen;
• aryl;
• heteroaryl;
• aryloxy;
• arylthio;
• cycloalkyl and heterocycloalkyl, wherein R′ and R″ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or an unsubstituted aryl group,
• wherein said linear or branched (C1-C6)alkyl groups, said linear or branched (C2-C6)alkenyl group, said linear or branched (C2-C6)alkynyl group, said linear or branched (C1-C6)alkoxy, said aryl, said heteroaryl, said aryloxy, said arylthio, said cycloalkyl, and said heterocycloalkyl are optionally substituted by from 1 to 3 groups selected from the group consisting of:
• linear or branched (C1-C6)alkyl;
• linear or branched (C2-C6)alkenyl group;
• linear or branched (C2-C6)alkynyl group;
• (C3-C6)spiro;
• linear or branched (C1-C6)alkoxy;
• (C1-C6)alkyl-S—;
• hydroxyl;
• oxo;
• N-oxide;
• nitro;
• cyano;
• —COOR′;
• —OCOR′;
• —NR′R″;
• R′CONR″—;
• NR′R″CO—;
• linear or branched (C1-C6)polyhaloalkyl;
• trifluoromethoxy;
• (C1-C6)alkylsulphonyl;
• halogen;
• aryl;
• heteroaryl;
• aryloxy;
• arylthio;
• cycloalkyl and heterocycloalkyl, wherein R′ and R″ independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group or an unsubstituted aryl group,
• its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, wherein the compound of formula (I) is administered alone or in combination with one or more pharmaceutically acceptable excipients.